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CLINICAL TRIAL STUDY
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Abstract:
Background:
Sustained Acoustic Medicine (SAM) is an emerging, non-invasive, non-narcotic, home-use ultrasound therapy for the daily treatment of joint pain.
The aim of this multi-site clinical study was to examine the efficacy of long-duration continuous ultrasound combined with a 1% diclofenac
ultrasound gel patch in treating pain and improving function in patients with knee osteoarthritis.
Methods:
The Consolidated Standards of Reporting Trials (CONSORT) were followed. Thirty-two (32) patients (18-males, 14-females) 54 years of average
age with moderate to severe knee pain and radiographically confirmed knee osteoarthritis (Kellgren-Lawrence (KL) grade II/III) were enrolled for
treatment with the SAM device and diclofenac patch applied daily to the treated knee. SAM ultrasound (3 MHz, 0.132 W/cm2, 1.3 W) and 6 grams
of 1% diclofenac were applied with a wearable device for 4 hours daily for 1 week, delivering 18,720 Joules of ultrasound energy per treatment.
The primary outcome was the daily change in pain intensity using a numeric rating scale (NRS 0-10), which was assessed prior to intervention
(baseline, day 1), before and after each daily treatment, and after 1 week of daily treatment (day 7). Rapid responders were classified as those
patients exhibiting greater than a 1-point reduction in pain following the first treatment. Change in Western Ontario McMaster Osteoarthritis
Questionnaire (WOMAC) score from baseline to day 7 was the secondary functional outcome measure. Additionally, a series of daily usability and
user experience questions related to devising ease of use, functionality, safety, and effectiveness, were collected. Data were analyzed using t-tests
and repeated measure ANOVAs.
Results:
The study had a 94% retention rate, and there were no adverse events or study-related complaints across 224 unique treatment sessions. Rapid
responders included 75% of the study population. Patients exhibited a significant mean NRS pain reduction over the 7-day study of 2.06-points
(50%) for all subjects (n=32, p<0.001) and 2.96-points (70%) for rapid responders (n=24, p<0.001). The WOMAC functional score significantly
improved by 351 points for all subjects (n=32, p<0.001), and 510 points for rapid responders (n=24, p<0.001). Over 95% of patients found the
device safe, effective and easy to use, and would continue treatment for their knee OA symptoms.
Conclusion:
Sustained Acoustic Medicine combined with 1% topical diclofenac rapidly reduced pain and improved function in patients with moderate to severe
osteoarthritis-related knee pain. The clinical findings suggest that this treatment approach may be used as a conservative, non-invasive treatment
option for patients with knee osteoarthritis. Additional research is warranted on non-weight bearing joints of the musculoskeletal system as well as
different topical drugs that could benefit from improved localized delivery.
Clinical Trial Registry Number: (NCT04391842).
Keywords: Sustained acoustic medicine, Sonophoresis, Diclofenac, Anti-steroidal anti-inflammatory drugs, Long-duration continuous ultrasound,
Low-intensity continuous ultrasound, Pain management.
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1. INTRODUCTION
Osteoarthritis (OA) affects 37.4% of adults in the United
States  over  the  age  of  60,  costing  the  American  economy
approximately  $60  billion  per  year  [1].  OA  development  is
related  to  genetic  factors,  aging,  obesity,  and  joint
misalignment  [2  -  5].  Progression  of  OA  is  associated  with
chronic  pain,  joint  instability,  stiffness,  narrowing,  and  joint
degeneration [3 - 7]. While the underlying mechanism of OA
progression  and  associated  pain  is  not  well  understood,
inflammation  plays  an  important  role  in  the  degradation  of
affected joints over time. Treatment of OA is limited to pain
management,  reducing  joint  stiffness,  improving  range  of
motion, function, and the patient's quality of life living with the
disease  [8].  Current  symptomatic  treatment  of  OA  includes
weight  loss,  exercise,  physical  therapy,  acupuncture,
therapeutic ultrasound, hyaluronic acid injection, systemic or
topical  application  of  nonsteroidal  anti-inflammatory  drugs
(NSAIDs), and surgical intervention. Many of these treatments
provide transient pain relief, break the integrity of the skin, and
have long term adverse side effects or procedural risk [8 - 15].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of
the  most  common  treatments  of  OA  and  have  been  used  to
manage  OA  associated  pain  for  decades.  Long-term  use  of
systemic  NSAIDs  have  adverse  effects  on  the  kidney,  liver,
and  gastrointestinal  system  [9,  16  -  18],  while  the  topical
application of NSAIDs has limited penetration through the skin
[9,  19].  Recently,  multiple meta-analyses have shown higher
efficacy  of  diclofenac  relative  to  other  NSAIDs  such  as
ibuprofen, celecoxib, and ketoprofen [20, 21]. Multiple studies
have  used  different  methods  to  increase  the  efficacy  of
diclofenac  penetration  through  the  skin,  such  as  using  skin
penetration  enhancers,  electroporation,  iontophoresis,  and
sonophoresis  [22  -  25].
Ultrasound  has  been  considered  a  potential  therapy  to
alleviate pain associated with OA progression [26 - 29].  The
effectiveness  of  ultrasound  therapy  is  highly  dependent  on
multiple  parameters  such as  intensity,  duty cycle,  frequency,
duration  of  application,  and  energy  dose  [30,  31].  Sustained
Acoustic Medicine (SAM) has emerged in the last decade as a
well-controlled, high-dose, home-use ultrasound treatment for
patients with musculoskeletal injuries [32 - 35]. Multiple meta-
analyses have shown that ultrasound with correct dosing can be
used  as  stand-alone  or  adjunctive  therapy  to  manage  OA
associated pain [29, 36 - 38]. Huang et al. (2005) showed the
effectiveness of ultrasound (25% duty, 1 MHz, 2.5 W/cm2) as
adjunct  OA  therapy  improving  physical  activity.  Patients
showed  an  increase  in  knee  range  of  motion  (ROM)  and  a
decrease in pain on the visual analog scale (VAS) after 8 weeks
of treatment [27].
Similarly, Yang et al. (2006) reported a significant increase
in VAS scores after 28 days for ultrasound treatment for OA
[39].  In  two  series  (n=12,  n=7)  of  SAM  wearable,  long-
duration, continuous ultrasound studies on knee OA, Langer et
al. (2014) reported that daily SAM treatment for 12 to 60 days
significantly reduced pain by 52% (2 to 4 -points improvement
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on the VAS),  and demonstrated a  20% improvement  in  joint
function  for  the  active  versus  placebo  treatment  group.  The
authors  concluded  that  the  SAM studies  were  underpowered
for the determination of clinical significance and that a larger
clinical trial was warranted [40]. Langer et al. (2015) reported
in a 47 patient, randomized placebo-controlled study (28 active
and  19  placebo)  on  SAM  treatment  of  radiographic  mild  to
moderate  clinical  knee  OA  (Grade  1–2  on  the  Osteoarthritis
Research  Society  International  (OARSI)  scale),  and
demonstrated that patients with moderate to severe pain had a
2.5-point  reduction  in  pain  on  the  VAS  over  42  days  of
treatment which was statistically significant over the placebo
1.23-point  decrease.  The authors  concluded that  reduction in
OA pain was clinically meaningful and exceeded The Initiative
on Methods, Measurements, and Pain Assessment in Clinical
Trials  (IMMPACT)  guidelines  [34].  In  a  double-blind,
randomized, placebo-controlled clinical trial on SAM treatment
for knee OA by Draper et al. (2018), 93 patients with moderate
to  severe  pain  and  mild  radiographic  knee  OA  (Kellgren-
Lawrence  grade  I/II)  had  a  significant  1.96-point  pain
reduction for active versus 0.85 point reduction for placebo on
a numeric rating scale (NRS). Patients receiving active SAM
treatment also had significant improvement in pain, stiffness,
and  function  on  the  Western  Ontario  and  McMaster
Universities (WOMAC) scale compared with placebo (500 vs.
311, respectively). The authors concluded that SAM treatment
significantly  reduced  pain  and  improved  joint  function  in
patients with moderate to severe OA knee pain and could be
used as a conservative treatment option for patients with knee
OA [33]. A recent 2019 systematic review and meta-analysis
on ultrasound dosing  for  knee  OA demonstrated  that  regular
ultrasound  treatment  significantly  relieved  pain  and  reduced
the  WOMAC  physical  function  score.  Ultrasound  also
increased the active range of motion and reduced the Lequesne
index. The authors concluded that regular ultrasound treatment
is safe and effective at relieving pain and improving physical
function in patients with knee OA [37, 41].  The objective of
this  study  was  to  determine  the  efficacy  of  long-duration
continuous ultrasound delivered by the SAM device combined
with 1% diclofenac for the symptomatic treatment of knee OA
pain.  We  hypothesized  that  combining  SAM  with  topical
diclofenac  would  provide  more  rapid  pain  reduction  for
patients  compared  with  prior  SAM  studies  reported  in  the
clinical  literature.
2. METHODS
The  study  and  methods  followed  the  Consolidated
Standards  of  Reporting  Trials  (CONSORT)  [42].  The
prospective multi-site study was conducted in the Central New
York and Southern Coastal Connecticut regions of the United
States  between  June  2019  and  January  2020  registered  with
ClinicalTrials.gov identifier NCT04391842. Patient enrollment
was  accomplished  through  referrals  from  Cayuga  Medical
Center  and  the  Yale-New  Haven  Health  System  community
hospitals,  to  Medical  Pain  Consultants  and  Sport  and
Orthopaedic  Physical  Therapy,  affiliated  outpatient  care
practices, respectively. The practices served as the setting for
enrollment,  training  on  the  use  of  the  device,  visits  of  the
patients  with  research  staff,  and  pre/post  functional
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measurements. The patient's home/work setting served as the
setting  at  which  the  device  was  self-administered  and  where
pain measurements were recorded. The study was approved by
the  institutional  review  board  of  the  Integ  Review,  and  all
patients  provided  informed  consent  to  participate.  The
procedures  followed  were  in  accordance  with  the  ethical
standards  of  the  responsible  committee  on  human
experimentation and with the Helsinki Declaration of 1975, as
revised in 2000 [43].
Included  patients  were  45  to  85  years  of  age,  reported
moderate to severe knee OA pain negatively affecting their life,
were  radiologically  confirmed  to  have  mild  to  moderate  OA
(Kellgren-Lawrence  (KL)  grade  II-III  score)  in  one  or  both
knees,  had  baseline  day-1  pain  Numerical  Rate  Score  (NRS
0-10) pain between 3 and 7, had no intraarticular injection to
the  treated  knee  in  the  last  6  months,  had  no  trauma  to  the
treated  knee,  and  had  no  implants  or  surgeries  to  the  treated
knee. In cases of bilateral knee OA, the more painful knee was
selected for treatment; if equal pain, a flip of a coin was used to
select the knee for treatment. Participants were excluded if they
had KL score greater than III, showed an inability to apply the
device, were currently using a steroid-based medication, had a
recent  history  of  trauma  to  the  knee  or  having  osteoarthritis
develop secondary to a metabolic disorder.
Patients meeting inclusion criteria were enrolled for a 7-
day treatment with SAM ultrasound device and 1% diclofenac
ultrasound coupling patch. Patients subsequently self-applied
the  respective  treatment  4  hours  per  day  for  1  week  to  the
lateral  and  medial  arthritic  knee,  as  shown  in  Fig.  (1).
Measurements  of  pain  before  and  after  daily  application  of
SAM and ease of  use were recorded in a daily patient  diary,
while functional measurements were completed during clinic
visits.
The clinical sample size for the study was determined from
Draper et al.  (2018) using the mean knee OA pain reduction
from SAM treatment for the first 2 weeks of the study (active
mean 3.61 ± 2.53) and mean baseline pain of the study group
(mean 5.53 ± 2.37); A sample size of 23 patients provided over
95%  power  for  the  primary  outcome  measure  NRS  pain
reduction. We conservatively targeted enrollment of 30 patients
anticipating  insignificant  (less  than  5%)  dropouts  for  the  1-
week study. We also anticipated a stronger treatment effect size
for pain reduction in our study since SAM was to be applied
for 4-hours with topical diclofenac per treatment versus only
SAM in Draper et al. (2018). Total participants completing the
study was slightly above target (+2).
2.1. Baseline Measurements and Intervention Protocol
The  patients'  initial  NRS  and  Western  Ontario  and
McMaster Universities Arthritis Index (WOMAC) scores were
recorded at the outpatient care facilities on Day 1 of the study.
Patients were trained to use the Sustained Acoustic Medicine
(SAM)  device  along  with  diclofenac  patch  and  record  NRS
pain scores before the treatment and post 4-hour treatment in
daily diaries for 7 days. SAM® Pro 2.0 (ZetrOZ Systems LLC,
Trumbull,  CT)  is  a  portable,  wearable,  US  Food  and  Drug
Administration  FDA-approved  Class  II  medical  device  for
prescription home-use ultrasound treatment. The SAM device
delivers  ultrasound  at  3  MHz,  100% duty  cycle,  1.3  W with
132  mw/cm2  intensity  per  transducer  and  overall  energy
delivery of 18,720 Joules over 4 hours of treatment. The device
is attached to the body with a disposable adhesive patch which
was  pre-filled  with  3g  ultrasonic  coupling  gel  with  1%
diclofenac  provided  by  the  manufacturer  (Fig.  1).
Fig. (1). Sustained Acoustic Medicine (SAM) ultrasound device applied to the medial and lateral articulation points of the knee with 1% diclofenac
ultrasound coupling patch.
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At  the  clinics,  patients  were  shown  how  to  apply  the
disposable  adhesive  patches/transducers  to  the  medial  and
lateral sides of the arthritic knee and set the medical devices
treatment timer for 4 hours of continuous ultrasound (Fig. 1).
Patients were instructed to wear the device during regular daily
activity  and  apply/remove  the  device  when  convenient  with
their  daily  schedule.  Each  patient  received  one  rechargeable
device and 18 disposable, single use, diclofenac ultrasound gel
adhesive patches. Patients were instructed to apply the device
daily and record pain and usability questions daily in the diary.
Patients recorded the primary outcome NRS (0 – 10, 0 = no
pain,  10 = extreme pain)  at  pre-treatment  and post-treatment
over 7 days. The secondary outcome WOMAC was recorded at
the outpatient care practices at the beginning of the study and
after  7  days  of  treatment,  evaluating  activity,  stiffness,  and
function of the treated knee.
2.2. Follow-up and Statistical Analysis
Once enrolled in the study, patients completed outpatient
care facility visits on day 1 (patient screening, enrollment and
informed consent)  and  day  7  (study  completion).  During  the
week,  the  research  staff  talked  with  the  patient  once  on  the
phone to review the daily pain diary, addressed any questions
the patient had about using the device or being involved in the
study,  and  monitored  for  any  adverse  events  (i.e.,  a  serious
unanticipated  injury  or  death)  or  reactions  (e.g.,  skin
sensitivity,  redness  or  burn)  from  the  device.
Change in NRS pain score from baseline was analyzed for
pre  and  post-treatment  each  treatment  day  throughout  the
study,  and  WOMAC (pain,  stiffness,  and  functional  change)
was evaluated on day 1 and day 7. Demographic and outcomes
data  were  analyzed  using  t-tests  and  repeated  measure
ANOVAs.  Based  on  the  primary  outcome  measure,  rapid
responders  were  considered  to  have  greater  than  a  1-point
reduction  in  pain  on  the  first  treatment.  Chi-squared
proportional  assessment  was  used  to  assess  gender
demographics between groups. Data analysis was conducted in
the R software environment  for  statistical  computing (The R
Foundation for Statistical Computing, Vienna, Austria). Data
are  expressed  as  means ± SDs  (standard  deviations).  The  p-
values  of  less  than  0.05  were  considered  statistically
significant.
3. RESULTS
A  total  of  38  patients  were  screened.  Thirty-four  [33]
patients were eligible and enrolled in the study. Thirty-two [31]
completed the study. The two dropouts were non-study related
on the first day of the protocol (one due to family and one due
to influenza), resulting in a 94% retention rate. A total of 18
males and 14 females completed the 7-day study (Fig. 2). The
patient  demographics  for  treatment  intervention  include
subjects with mean age 53.6 ± 8.5 years and body mass index
(BMI) 32.8 ± 8.8. Patients reported moderate knee OA pain at
baseline, average NRS 4.06± 2.39. No significant differences
or  trends  were  found  between  baseline  pain  and  BMI  by
gender.  Approximately  62%  (20  patients)  of  the  study
population  were  non-Hispanic  Caucasian  and  38%  (12
patients)  non-Hispanic  African  American.  Enrolled  patients
were currently seeing medical care for knee osteoarthritis pain.
The most common pain medications were prescription NSAIDs
and  oxycodone.  The  most  common  non-drug  pain  treatment
was physical therapy and light exercise. Cointervention results
were not investigated in this study.
















Participant Screened N= 38 
Participant Enrolled (n=34) 
Participant Excluded 
- Intraarticular injections 
- Surgeries in past six months 
- Use of opioid-based medication 
- Implants or trauma 
All Participants (n=32) 
Rapid Responders (n=24) 
>1 point NRS change Day 1 
Day 1 – Participants’ WOMAC 
recorded 
Day 7 – Participants’ WOMAC 
recorded 
Day 1 – 7 Pre-Treatment 
and Post-Treatment NRS 
Score recorded  
Drop out - 2 
(1-family issues, 1 influenza 
Participant Included - All 
- 45 – 85 years of age 
- Mild to moderate OA (KL II/III) 
- NRS Score ≥ 3 
Participant Included – Rapid Responders 
- 1-point drop in NRS on 1 day 
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Fig. (3). Numeric Rating Score: A) “All Subjects n=32” NRS pain showing significant decrease in pain from day 1 through day 7 of treatment. Pain
was reduced by 50% from start to end of study (2.06 NRS, p<0.001). B) “Rapid Responder n=24” NRS showing significant decrease over 7 days of
study. Pain was reduced by 70% from start to end of study (2.96 NRS, p<0.001).
3.1. Primary Outcome Measure of Knee OA Reduction in
Pain on NRS Scale
Knee  osteoarthritis  pain  was  significantly  reduced  daily
and over the course of the 7-day treatment regimen for both the
entire study cohort (100%, n=32) and rapid responders (75%,
n=24).  For  the  entire  patient  cohort,  the  pretreatment  day  1
baseline pain was 4.06 ± 2.39, and after 7 days of treatment,
pain decreased to 2.00 ± 2.41, 2.06-point change 7 days (50%
decrease,  p<0.001,  Fig.  3A).  The  application  of  SAM  with
diclofenac patch provided the largest significant daily decrease
in pain on the first two days of the study with continued pain
reduction thereafter (Fig. 3).
Rapid responders showed a more significant reduction in
the  NRS  pain  score.  Day  1  baseline  pain  of  4.26  ±  2.41  to
1.30± 1.5, 2.96-point decrease (70% decrease, p<0.001) over 7
days  of  treatment  (Fig.  3B).  Pain  reduction  significantly
decreased daily from baseline day 1 to day 2 to day 3…day 7
(Fig. 3).
3.2. Secondary Outcome of Knee Functional Improvement
on WOMAC Scale
The  WOMAC  score  measuring  the  change  in  pain,
stiffness,  and  functionality  of  the  knee  was  significantly
improved for SAM with diclofenac patch by 351 points for all
subjects  (n=32,  p<0.001,  Fig.  4A),  and  510  points  for  rapid
responders  (n=24,  p<0.001,  Fig.  4B).  For  all  subjects,  pain
score  improved  by  66-points  (p<0.0001),  stiffness  score
improved  by  41  points(p<0.001),  and  functionality  score
improved  by  244  points  (p<  0.001)  (Table  1).  For  rapid
responders,  pain  score  improved  by  92  points  (p<0.0001),
stiffness  score  improved  by  55  points  (p<0.0001),  and
functionality score improved by 364 points (p<0.0001) (Table
2).
Table  1.  WOMAC table  for  all  subjects  n=32:  Shows  the  baseline  score  and  score  after  7  days  of  treatment.  SAM with
diclofenac significantly reduced pain and stiffness and improved functionality.
- Pre-Treatment Post-Treatment Mean 95% CI p value
WOMAC Pain 240 ± 110 173 ± 146 -101 to -32 0.0005
WOMAC Stiffness 125 ± 42 84 ± 61 -61 to -22 0.0002
WOMAC Functionality 803 ± 393 559 ± 481 -356 to -132 0.0001
WOMAC Total 1168 ± 528 816 ± 678 -508 to -195 < 0.0001
Table  2.  WOMAC table  for  rapid responders  n=24:  Shows better  response to  SAM with diclofenac treatment than “All
Subjects” with significant decreases in pain and stiffness, and improved functionality over 7 days of treatment.
- Pre-Treatment Post-Treatment Mean 95% CI p Value
WOMAC Pain 235.42 ± 108.33 143.75 ± 140.73 -132.9 to -50.41 0.0005
WOMAC Stiffness 124.96 ± 40.38 69.79 ± 60.37 -81.76 to -28.57 < 0.0001
WOMAC Functionality 800.22 ± 393.48 436.46 ± 445.05 -557.3 to -170.2 < 0.0001
WOMAC Total 1160.59 ± 480.81 650 ± 635.62 -745.2 to -276.0 < 0.0001
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Fig. (4). WOMAC Functional Score: A) Significant 351-point (p<0.001) decrease in WOMAC score after 7 days of SAM with diclofenac treatment
in all subjects n=32. B) Rapid Responders n=24 shows more robust 510-point (p<0.001) WOMAC decrease in response to the SAM with diclofenac
treatment over 7 days.
3.3.  Secondary  Outcome  of  Treatment  Usability  and
Satisfaction
There were no adverse events or study-related complaints
across 224 unique treatment sessions. There were no reports of
skin  burn,  skin  irritation,  or  skin  sensitization.  Over  95% of
patients found the device safe, effective, and relatively easy to
use and would continue treatment for their knee OA symptoms.
By day 7 of the study, 100% of patients in the study reported
the device was very easy to use and apply.
4. DISCUSSION
Osteoarthritis (OA) is a progressive disease of the joints,
resulting in the degradation of cartilage and bone, leading to a
reduction of joint space and increased inflammatory response
over  time  [3,  7,  44].  NSAIDs,  along  with  physical  therapy,
have shown limited efficacy in managing OA associated pain
[9, 14, 19, 26, 44, 45]. For many patients, the risks associated
with  the  long-term  systemic  use  of  NSAIDs  outweigh  the
modest  benefit.  While  a  localized,  topical  application  of
NSAIDs is safer for knee OA pain, the efficacy is limited due
to  drug  delivery  rates  through  and  across  the  skin  [9,  46].
Diclofenac is one of the more effective and prescribed NSAIDs
for OA associated pain [20, 21, 38, 47, 48]. This study used a
wearable multi-hour sustained acoustic medicine (SAM) device
with  1%  diclofenac  patch  to  treat  OA  associated  pain  and
improve mobility and overall quality of life of patients. SAM
applies  continuous  long-duration  ultrasound  along  with
localized delivery of diclofenac to decrease patients' knee OA
pain and improve joint function. In prior preclinical research,
SAM  has  demonstrated  the  3.8x  increase  of  diclofenac
penetration  into  and  across  the  skin  [49],  along  with  drug
delivery  enhancement  of  other  drugs  over  4-hour  treatment
protocols [49, 50].
The wearable SAM device and 1% diclofenac ultrasound
gel patch could be successfully self-applied by patients for use
in the home, providing significant pain relief of KL grade II/III
knee  OA.  No  adverse  events  were  noted  in  the  study
population,  and  94%  of  participants  completed  the  study.
Participants in the study had between a 50% (2.06-point) to a
(70%, 2.96-point) pain reduction on the NRS scale. The NRS
pain data show an incremental decrease in pain throughout the
7-day  treatment  with  the  highest  rate  of  reduction  in  pain
during the first two days. This outcome may be explained by
increased penetration of diclofenac into the joint space leading
to  inhibition  of  COX1  and  COX2  pathways  [20,  38],  thus
relieving the inflammatory response in the joint. Masterson et
al. (2020) demonstrated SAM increased transdermal diclofenac
delivery  3.8  fold  greater  than  topical  application  alone  [51],
which were similar to the results of transdermal salicylic acid
delivery with SAM by Langer et al. (2013) [49]. The sustained
treatment and continued pain reduction over the 7-days suggest
the  potential  of  lower  levels  of  cytokines  to  retain  pain  at  a
decreased  intensity.  Functionally,  the  WOMAC  score
improved significantly for patients with KL grade II/III knee
OA  by  351  points  for  all  subjects  (n=32,  p<0.001)  and  510
points for rapid responders (n=24, p<0.001). The improvement
in the WOMAC score is indicative of the overall improvement
of function and quality of life.
Ultrasound  has  been  shown  to  be  an  effective  pain
management method for arthritis-associated knee pain [29, 37,
45,  52  -  56].  Draper  et  al.  (2018)  demonstrated  a  1.96-point
pain  reduction  on  NRS  and  improvement  in  total  WOMAC
score by 505 points comparing the application of SAM active
continuous long-duration ultrasound to the placebo group in a
93-subject  double-blind,  randomized  controlled  study  [33].
This resulted in a 40% knee OA pain reduction for the active
treatment  group  and  a  16%  pain  reduction  for  the  placebo
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group over 6 weeks of daily treatment. In the current study, we
found a 50-70% pain reduction in 1 week of daily SAM with
diclofenac  patch  treatment  (Fig.  5).  Similarly,  Langer  et  al.
(2014, 2015) reported a 40% and 48% reduction in knee OA
pain after  6 weeks of  daily SAM treatment  in two pilot  case
series and one placebo-controlled study, including 66 subjects
in total. The current study did not include a placebo group but
had  similar  inclusion  criteria,  baseline  pain,  the  severity  of
knee  OA  (KL  grade  II/III),  and  patient  demographics.
Therefore,  the  more  rapid  and  robust  pain  reduction  can  be
attributed to the addition of the 1% diclofenac ultrasound gel
coupling  patch.  Yang  et  al.  (2006)  has  also  reported  on  the
efficacy  of  ultrasound  in  the  reduction  of  pain  with  a
combination  of  NSAIDs  [39].
Sustained  therapeutic  ultrasound  has  also  been  shown to
contribute  to  improved  cartilage  thickness.  Özgönenel  et  al.
(2018)  has  reported  that  the  application  of  continuous
therapeutic  ultrasound  in  30  patients  showed  a  significant
reduction in visual analog scale (VAS) and WOMAC scores,
and  improved  cartilage  thickness  in  medial  femoral  condyle
after  10  sessions  of  treatment  in  a  double-blinded  trial  [31].
Loyola-Sánchez et al. (2012) also reported encouraging effects
of ultrasound application in managing mild to moderate knee
OA in a double-blinded randomized study in 27 patients with a
significant increase in cartilage thickness after 20 sessions [57].
Additionally,  recent  studies  and  meta-analysis  show  the
efficacy  of  ultrasound  on  knee  OA  pain.  Still,  the  clinical
outcome significantly depends on ultrasound parameters such
as  1-3MHz frequency,  duty cycle,  duration,  and total  energy
delivered over treatment time [29, 45, 55].
The  FDA  approved  non-invasive  prescription  home-use
SAM device  has  little  to  no adverse  effects  reported and the
contraindications  are  similar  to  traditional  therapeutic
ultrasound [33 - 35, 40, 58]. The SAM device with a diclofenac
patch delivers 18,720 Joules of ultrasonic energy and 6g of 1%
diclofenac ultrasound gel daily to the arthritic knee of patients.
The continuous long-duration ultrasound treatment and locally
delivered  diclofenac  reduce  patient  pain  and  improve  joint
function  without  requiring  systemic  NSAID  use.  The
application of SAM to the joint also has diathermic effects [35,
59], which increase the blood flow, oxygenation, and exchange
of nutrients. The SAM diclofenac patch ensures ease of patient
application of localized diclofenac delivery and a decrease of
cytokines  such  as  cyclooxygenase  1  and  2,  interleukine  1  β,
TNF  α,  and  relative  pathways  [19,  44,  60  -  65].  The
mechanotransductive force of long duration ultrasound along
with  increased permeability  and transport  kinetics  across  the
skin  leads  to  increased  drug  penetration  through  the  skin  as
well  as  increased  blood  flow,  which  increases  the  drug
penetration  into  the  affected  tissue  [39,  41,  66  -  69].
Recent  preclinical  and  clinical  studies  have  shown  that
ultrasound therapy has chondroprotective effects by inhibiting
inflammatory  factors  [36,  52,  64,  70  -  72].  The  combined
enhanced  drug  delivery  of  diclofenac  and  ultrasound
chondroprotective  effect  makes  SAM  combined  with
diclofenac an effective treatment for arthritis associated pain.
The  current  study  shows  the  efficacy  of  SAM  with  a  1%
diclofenac ultrasound coupling patch in OA patients in a home-
use  environment,  with  a  significant  clinically  meaningful
decrease  in  pain  and  joint  stiffness  and  an  increase  in
functionality and overall quality of life. While the current study
did not evaluate the effect of SAM on cartilage, given the short
duration of  the study,  future research is  needed to  determine
the role of sustained, continuous ultrasound as an OA disease-
modifying agent.
Fig. (5). Pain reduction of current study compared with Draper et al. (2018). One week of daily SAM with diclofenac patch treatment provides an
additional 10% to 30% pain reduction for patients 5 weeks faster than prior reported literature for long-duration ultrasound treatment.
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The SAM device is one of two prescription home-use (1 to
3MHz)  ultrasound  devices  available  in  the  USA.  The  other
device (Exogen®, Bioventus LLC, Durham, NC) was approved
by the FDA in the early 1990s for non-thermal application and
used  a  pulsed  20-minute  daily  ultrasound  treatment  at  a  low
energy level (140 Joules per 20-minute treatment) [73, 74]. The
SAM  energy  level  is  approximately  133  times  greater  and
therefore generates significant thermal and non-thermal effects
on  tissue.  The  SAM  devices  used  in  this  study  cost  $6800,
which is significantly less costly than surgery or comorbidities
developed from systemic drug use for chronic diseases. SAM
treatment should be considered for patients with moderate knee
OA  pain  as  a  cost  conservative  treatment  option.  Future
research on long-duration ultrasound as a means for localized
drug  delivery  of  NSAID  and  reduced  osteoarthritis  disease
progression  is  of  great  interest.  Additional  studies  could
evaluate  the  dosimetry  of  SAM  and  NSAID  to  provide
clinically meaningful pain reduction further while minimizing
the  use  of  drugs.  The  use  of  SAM  with  other  topical  agents
such  as  dexamethasone  before,  during,  and  after  SAM
treatment  may  also  be  of  interest  to  the  clinical  community
[75].
CONCLUSION
Sustained Acoustic Medicine with diclofenac patch rapidly
reduced pain and improved joint function in patients with knee
osteoarthritis  pain.  The  clinical  findings  suggest  the  long-
duration  continuous  ultrasound  therapy  with  diclofenac  can
provide  significant  rapid  pain  reduction  for  patients  with
osteoarthritis. The use of SAM device and diclofenac should be
considered  for  patients  with  moderate  pain,  requiring  a  fast-
acting intervention in the home setting.
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